anxiety disorders

Overview

Anxiety disorders are a group of common psychiatric conditions characterized by excessive fear, worry, and related behavioral or physiological symptoms that are persistent, distressing, and functionally impairing. Clinically, they include several diagnostic subtypes, but they share core features such as heightened threat sensitivity, autonomic arousal, avoidance behavior, and difficulty regulating anxious responses. They are important contributors to global disability and frequently co-occur with depression, sleep disturbance, post-traumatic stress symptoms, and chronic medical illness.

Biologically and medically, anxiety disorders are studied as complex, multifactorial conditions influenced by neurobiological signaling, stress-response pathways, psychological resilience, and environmental exposures. In recent research, they have been examined both as primary psychiatric outcomes and as comorbid conditions in cancer, fibromyalgia, multiple sclerosis, epilepsy, and pediatric illness. They are also increasingly evaluated in relation to supportive care interventions, digital mental health tools, and predictive modeling from structured electronic health records.

Focus of Latest Publications

Recent publications have examined anxiety disorders across a wide range of clinical settings, often alongside depression, insomnia, disability, or other comorbid symptoms. Several studies focused on interventions or supportive approaches intended to reduce anxiety symptoms, including non-pharmacological strategies in Parkinson’s disease, internet-delivered cognitive behavioural therapy in adults with multiple sclerosis, and laughter yoga in children with autism spectrum disorder and their parents. Other work assessed anxiety in relation to somatic complaints in tinnitus patients, social support and psychological resilience in colorectal cancer, and preoperative mental health in frozen shoulder patients undergoing manipulation under anesthesia.

Interventional studies reported promising symptom reductions in some settings. In a randomized controlled trial of virtual reality glasses used during inhaler treatment in children, the intervention group showed significantly lower post-treatment anxiety and fear scores than controls. A randomized controlled trial of internet-delivered cognitive behavioural therapy in adults with multiple sclerosis evaluated effects on depression, anxiety, and disability, while the Parkinson’s disease publication was a protocol for a Cochrane Review designed to compare the efficacy and safety of non-pharmacological interventions for reducing anxiety and depression symptoms. The laughter yoga study was also a feasibility protocol, aiming to assess recruitment, adherence, acceptability, safety, and potential effects on anxiety and depression in children with autism spectrum disorder.

Other studies primarily explored associations and risk patterns rather than treatment effects. A cross-sectional study in colorectal cancer patients examined how multidimensional social support relates to anxiety and depression, with psychological resilience as a mediator. A retrospective case-control study used structured electronic health records and area-based health measures to compare machine learning and deep learning models for classifying pediatric patients at risk for anxiety disorders, aiming to support proactive monitoring across developmental stages. In cancer populations, a nationwide study estimated the incidence of anxiety disorder after diagnosis across five major cancer types and characterized psychotropic pharmacotherapy patterns. Additional work in tinnitus patients investigated links between somatic complaints and symptoms of anxiety and depression, highlighting the relevance of anxiety assessment in broader rehabilitation and symptom evaluation.